MARKET

STRO

STRO

Sutro Biopharma
NASDAQ
5.65
+0.72
+14.60%
After Hours: 5.55 -0.1 -1.77% 19:59 03/28 EDT
OPEN
4.970
PREV CLOSE
4.930
HIGH
6.13
LOW
4.970
VOLUME
3.14M
TURNOVER
0
52 WEEK HIGH
6.13
52 WEEK LOW
2.005
MARKET CAP
352.80M
P/E (TTM)
-3.1831
1D
5D
1M
3M
1Y
5Y
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. The company reported a wider-than-expected fourth-quarter loss. Avalo Therapeutics, Inc. Shares jumped 430% in today's mid-day session. Other stocks moving in the market include RH, Ggoorks and Xilio.
Benzinga · 7h ago
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
REX American Resources Corporation shares jumped 23.2% to $54.15 after upbeat quarterly earnings. Avalo Therapeutics, Inc. Shares gained 430% in Thursday's session. The S&P 500 gained around 0.1% on Thursday. RH posted weaker-than-expected results for its fourth quarter.
Benzinga · 10h ago
Sutro Biopharma Is Maintained at Outperform by Oppenheimer
Dow Jones · 13h ago
Sutro Biopharma Price Target Maintained With a $10.00/Share by Oppenheimer
Dow Jones · 13h ago
Oppenheimer Maintains Outperform on Sutro Biopharma, Maintains $10 Price Target
Benzinga · 14h ago
VERI, CHEK and MESO are among pre market gainers
VERI, CHEK and MESO are among pre market gainers. Mesoblast (MESO) and Cazoo Group (CZOO) are among the biggest pre market losers. Krispy Kreme and AirNet Technology are also on the move.
Seeking Alpha · 1d ago
Navigating 4 Analyst Ratings For Sutro Biopharma
Sutro Biopharma Inc is a clinical-stage drug discovery, development and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders. Four analysts have provided ratings for Sutro biopharma in the past three months. Sutro has an average price target of $11.75 and a decline of 7.26% from the prior average.
Benzinga · 1d ago
Sutro Biopharma Is Maintained at Outperform by Oppenheimer
Dow Jones · 1d ago
More
About STRO
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It provides two wholly owned ADCs in the clinic, namely luveltamab tazevibulin (STRO-002 or luvelta) and STRO-001. STRO-002 is an ADC directed against folate receptor-alpha (FolRa) for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. STRO-001 is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma (NHL). Its preclinical product candidate, STRO-003, is a single homogeneous ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), developed for the treatment of solid tumors.

Webull offers Sutro Biopharma Inc stock information, including NASDAQ: STRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STRO stock methods without spending real money on the virtual paper trading platform.